治疗方案-话题@MedSci

#治疗方案#

313篇内容 | 3240人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1905167, encodeId=3779190516eff, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=JAMA Netw Open：晚期口咽鳞状细胞癌的更佳初始治疗方案？, objectType=article, longId=212280, objectId=7c662122804b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c662122804b, replyNumber=0, likeNumber=79, createdTime=2021-06-10, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c662122804b, moduleTitle=JAMA Netw Open：晚期口咽鳞状细胞癌的更佳初始治疗方案？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c662122804b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905162, encodeId=0b4519051627b, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=JAMA Oncol：Tislelizumab联合化疗作为晚期鳞状非小细胞肺癌的一线治疗方案疗效显著, objectType=article, longId=209616, objectId=c0a520961635, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0a520961635, replyNumber=0, likeNumber=72, createdTime=2021-11-27, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0a520961635, moduleTitle=JAMA Oncol：Tislelizumab联合化疗作为晚期鳞状非小细胞肺癌的一线治疗方案疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0a520961635)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905138, encodeId=61431905138ef, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=NEJM：3天阿莫西林治疗方案用于儿童吸入性肺炎, objectType=article, longId=196947, objectId=91c819694e49, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91c819694e49, replyNumber=0, likeNumber=50, createdTime=2020-11-30, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91c819694e49, moduleTitle=NEJM：3天阿莫西林治疗方案用于儿童吸入性肺炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91c819694e49)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905161, encodeId=4363190516152, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=Lancet：杜鲁特韦-恩曲他滨-替诺福韦艾拉酚胺治疗方案是目前更安全有效的孕妇HIV治疗方案, objectType=article, longId=209575, objectId=f6e92095e5f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6e92095e5f3, replyNumber=0, likeNumber=0, createdTime=2021-09-18, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6e92095e5f3, moduleTitle=Lancet：杜鲁特韦-恩曲他滨-替诺福韦艾拉酚胺治疗方案是目前更安全有效的孕妇HIV治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6e92095e5f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905147, encodeId=a08a190514e93, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=Br J Cancer：FOLFIRI治疗方案与西妥昔单抗或贝伐单抗联合治疗晚期结直肠癌的FIRE-3 3期随机临床研究, objectType=article, longId=203464, objectId=b4f620346485, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4f620346485, replyNumber=0, likeNumber=93, createdTime=2021-01-21, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4f620346485, moduleTitle=Br J Cancer：FOLFIRI治疗方案与西妥昔单抗或贝伐单抗联合治疗晚期结直肠癌的FIRE-3 3期随机临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4f620346485)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905134, encodeId=02f6190513483, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=Clin Infect Dis：耐药肺结核患者接受含贝达奎林或德拉米尼的治疗方案的临床结果, objectType=article, longId=191921, objectId=bb121919210c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb121919210c, replyNumber=0, likeNumber=53, createdTime=2020-12-13, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb121919210c, moduleTitle=Clin Infect Dis：耐药肺结核患者接受含贝达奎林或德拉米尼的治疗方案的临床结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb121919210c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905131, encodeId=9e88190513187, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=Blood：三种阿司匹林治疗方案在优化特发性血小板增多症患者抗血小板治疗比较, objectType=article, longId=191811, objectId=2d0619181140, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d0619181140, replyNumber=0, likeNumber=86, createdTime=2020-06-13, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d0619181140, moduleTitle=Blood：三种阿司匹林治疗方案在优化特发性血小板增多症患者抗血小板治疗比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d0619181140)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905127, encodeId=8ddf190512e06, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=王慧娟教授：达可替尼优势明显，一线治疗方案选择需考虑多重因素, objectType=article, longId=190282, objectId=410b19028294, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=410b19028294, replyNumber=0, likeNumber=56, createdTime=2020-08-31, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=410b19028294, moduleTitle=王慧娟教授：达可替尼优势明显，一线治疗方案选择需考虑多重因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=410b19028294)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905135, encodeId=7afa190513560, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=J Sex Med：患者对初始PDE-5抑制剂治疗方案的依从性, objectType=article, longId=192995, objectId=a6021929952a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6021929952a, replyNumber=0, likeNumber=57, createdTime=2021-01-14, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6021929952a, moduleTitle=J Sex Med：患者对初始PDE-5抑制剂治疗方案的依从性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6021929952a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905151, encodeId=6770190515120, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=在急性期植入颈动脉支架？或许还有更优的治疗方案！, objectType=article, longId=205133, objectId=d5f320513377, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5f320513377, replyNumber=0, likeNumber=0, createdTime=2021-04-30, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5f320513377, moduleTitle=在急性期植入颈动脉支架？或许还有更优的治疗方案！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5f320513377)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905142, encodeId=659d1905142bd, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=Circulation：我们该何时进行降脂治疗？他汀治疗方案新进展！, objectType=article, longId=198457, objectId=5e9c19845e4d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e9c19845e4d, replyNumber=0, likeNumber=28, createdTime=2021-04-29, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e9c19845e4d, moduleTitle=Circulation：我们该何时进行降脂治疗？他汀治疗方案新进展！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e9c19845e4d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905123, encodeId=74d0190512383, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=Virol J：基于Sofosbuvir的治疗方案对于感染了4-5期慢性肾脏病的丙型肝炎患者是安全有效的, objectType=article, longId=189222, objectId=4cd318922243, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cd318922243, replyNumber=0, likeNumber=82, createdTime=2020-03-22, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cd318922243, moduleTitle=Virol J：基于Sofosbuvir的治疗方案对于感染了4-5期慢性肾脏病的丙型肝炎患者是安全有效的, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cd318922243)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905146, encodeId=d38b19051461e, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=罗氏泰圣奇®免疫联合治疗方案在中国获批用于治疗肝细胞癌, objectType=article, longId=202585, objectId=09a2202585ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09a2202585ad, replyNumber=0, likeNumber=75, createdTime=2021-05-27, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09a2202585ad, moduleTitle=罗氏泰圣奇®免疫联合治疗方案在中国获批用于治疗肝细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=09a2202585ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905128, encodeId=4c931905128e2, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=含德拉马尼治疗方案在成人和儿童（≥6岁）耐药结核病患者中的“同情用药”, objectType=article, longId=190635, objectId=0f5b19063503, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f5b19063503, replyNumber=0, likeNumber=79, createdTime=2020-07-14, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f5b19063503, moduleTitle=含德拉马尼治疗方案在成人和儿童（≥6岁）耐药结核病患者中的“同情用药”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f5b19063503)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905124, encodeId=4a971905124ee, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=“新冠肺炎上海治疗方案”：关键是关口前移，病在防不在治, objectType=article, longId=189481, objectId=9f77189481d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f77189481d7, replyNumber=0, likeNumber=51, createdTime=2020-06-19, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f77189481d7, moduleTitle=“新冠肺炎上海治疗方案”：关键是关口前移，病在防不在治, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f77189481d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905126, encodeId=3c26190512625, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=尸检能否“颠覆”新冠治疗方案？量不够，目前基本思路无变化, objectType=article, longId=189643, objectId=869518964344, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=869518964344, replyNumber=0, likeNumber=68, createdTime=2021-01-01, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=869518964344, moduleTitle=尸检能否“颠覆”新冠治疗方案？量不够，目前基本思路无变化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=869518964344)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905143, encodeId=dee0190514338, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=Am J Pathol：对于COVID-19重症患者，输注康复期血浆是一种安全的治疗方案, objectType=article, longId=199002, objectId=102119900214, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=102119900214, replyNumber=0, likeNumber=76, createdTime=2020-10-05, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=102119900214, moduleTitle=Am J Pathol：对于COVID-19重症患者，输注康复期血浆是一种安全的治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=102119900214)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905122, encodeId=8561190512210, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=Nat Rev Drug Dis：新冠病毒治疗方案, objectType=article, longId=187888, objectId=e1e318e888c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1e318e888c1, replyNumber=0, likeNumber=0, createdTime=2020-09-24, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1e318e888c1, moduleTitle=Nat Rev Drug Dis：新冠病毒治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1e318e888c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905137, encodeId=1957190513ee3, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=J Endod：颈环外吸收的容积评估方法以及它与分类、治疗方案和期望预后之间的联系, objectType=article, longId=195437, objectId=88f119543ec3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88f119543ec3, replyNumber=0, likeNumber=70, createdTime=2020-12-01, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88f119543ec3, moduleTitle=J Endod：颈环外吸收的容积评估方法以及它与分类、治疗方案和期望预后之间的联系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88f119543ec3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1905117, encodeId=16ce190511e4d, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, objectTitle=西安杨森宣布旗下新一代前列腺癌治疗方案安森珂®在华获批, objectType=article, longId=183746, objectId=ed7f183e4699, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed7f183e4699, replyNumber=0, likeNumber=67, createdTime=2020-07-09, rootId=0, userName=zhangjiqing, userId=5ee4187, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed7f183e4699, moduleTitle=西安杨森宣布旗下新一代前列腺癌治疗方案安森珂®在华获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed7f183e4699)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

治疗方案

2020-05-29

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

JAMA Netw Open：晚期口咽鳞状细胞癌的更佳初始治疗方案？

2021-06-10

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

JAMA Oncol：Tislelizumab联合化疗作为晚期鳞状非小细胞肺癌的一线治疗方案疗效显著

2021-11-27

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

NEJM：3天阿莫西林治疗方案用于儿童吸入性肺炎

2020-11-30

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

Lancet：杜鲁特韦-恩曲他滨-替诺福韦艾拉酚胺治疗方案是目前更安全有效的孕妇HIV治疗方案

2021-09-18

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

Br J Cancer：FOLFIRI治疗方案与西妥昔单抗或贝伐单抗联合治疗晚期结直肠癌的FIRE-3 3期随机临床研究

2021-01-21

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

Clin Infect Dis：耐药肺结核患者接受含贝达奎林或德拉米尼的治疗方案的临床结果

2020-12-13

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

Blood：三种阿司匹林治疗方案在优化特发性血小板增多症患者抗血小板治疗比较

2020-06-13

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

王慧娟教授：达可替尼优势明显，一线治疗方案选择需考虑多重因素

2020-08-31

zhaojie88 (审核中...)

前往app查看评论内容

#治疗方案#

J Sex Med：患者对初始PDE-5抑制剂治疗方案的依从性

2021-01-14

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

在急性期植入颈动脉支架？或许还有更优的治疗方案！

2021-04-30

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

Circulation：我们该何时进行降脂治疗？他汀治疗方案新进展！

2021-04-29

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

Virol J：基于Sofosbuvir的治疗方案对于感染了4-5期慢性肾脏病的丙型肝炎患者是安全有效的

2020-03-22

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

罗氏泰圣奇®免疫联合治疗方案在中国获批用于治疗肝细胞癌

2021-05-27

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

含德拉马尼治疗方案在成人和儿童（≥6岁）耐药结核病患者中的“同情用药”

2020-07-14

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

“新冠肺炎上海治疗方案”：关键是关口前移，病在防不在治

2020-06-19

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

尸检能否“颠覆”新冠治疗方案？量不够，目前基本思路无变化

2021-01-01

zhouqu_8 (审核中...)

前往app查看评论内容

#治疗方案#

Am J Pathol：对于COVID-19重症患者，输注康复期血浆是一种安全的治疗方案

2020-10-05

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

Nat Rev Drug Dis：新冠病毒治疗方案

2020-09-24

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

J Endod：颈环外吸收的容积评估方法以及它与分类、治疗方案和期望预后之间的联系

2020-12-01

zhangjiqing (审核中...)

前往app查看评论内容

#治疗方案#

西安杨森宣布旗下新一代前列腺癌治疗方案安森珂®在华获批

2020-07-09

科室
- - 订阅+
  - 更多科室
工具
服务